AR016283A1 - Uso de compuestos derivados de bis-indol, compuestos de bis-indol y composiciones farmaceuticas que contienen una dosificacion efectiva de por lo menosun compuesto derivado de bis-indol - Google Patents
Uso de compuestos derivados de bis-indol, compuestos de bis-indol y composiciones farmaceuticas que contienen una dosificacion efectiva de por lo menosun compuesto derivado de bis-indolInfo
- Publication number
- AR016283A1 AR016283A1 ARP980103029A ARP980103029A AR016283A1 AR 016283 A1 AR016283 A1 AR 016283A1 AR P980103029 A ARP980103029 A AR P980103029A AR P980103029 A ARP980103029 A AR P980103029A AR 016283 A1 AR016283 A1 AR 016283A1
- Authority
- AR
- Argentina
- Prior art keywords
- bis
- carboxy
- hydrogen
- indol
- group
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 1
- -1 hydroxy, hydroxymethyl Chemical group 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 150000002431 hydrogen Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229910018828 PO3H2 Inorganic materials 0.000 abstract 3
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 2
- 229910052794 bromium Inorganic materials 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000005079 alkoxycarbonylmethyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 239000002257 antimetastatic agent Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical group ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 abstract 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Uso de compuestos derivados de bis-indol de formula general (I), en donde: R y R son seleccionados en forma independiente de grupos hidrogeno,hidroxi, cloro, bromo, yodo, fluor, C1-6 alquilo, C1-4 alcoxi, C1-4 aciloxi, amino, mono-C1-4-alquilamino, di-C1-4alquilamino, -SH, C1-4 alquiltio, carboxi,C1-4 alcoxicarbonilo; R1 y R1 son seleccionados en forma independiente de grupos hidrogeno, hidroxi, hidroximetilo, amino, carboxi, C1-4 alquilo, A es ungrupo fenilo o naftilo sustituido por lo menos por un grupo seleccionado de hidroxi, carboxi, -SH, -CONHOH o -PO3H2, o bien es un heterociclo de 5- o 6-miembros que contiene uno o dos heteroátomos seleccionados de oxígeno, nitrogeno o azufre, que pueden estar opcionalmente benzocondensados y/o sustituidospor lo menos por un grupo seleccionado de piridilo, -SH, -PO3H2, carboxi o -CONHOH, o es un grupo de formula -(CH2)n-X, en el cual n es cero o el entero de 1o 2; y X es seleccionado de -SH, -PO3H2, -CONHOH, carboxi, amino, mono- C1-4 alquilamino, di-C1-4 alquilamino, enantiomeros, diaestereoisomeros, racematos ymezclas de los mismos, así como también sales de los mismos con ácidos y bases farmacéuticamente aceptables, como agentes antitumorales y antimetastásicos.Compuestos derivados de bis-indol segun la formula general (I), excluidos los siguientes compuestos: aquéllos en los cuales R, R, R1, R1 son hidrogeno yA es piridil 2-furanilo, 2-tienilo, carboxi, metoxicarbonilo, C1-4 alcoxicarbonilmetilo, 2- o 4-hidroxifenilo, 3,4-dihidroxifenilo; R1, R1 son hidrogeno,R y R son 6-bromo y A es un grupo aminometilo; R1, R1 son hidrogeno, R y R son 5-cloro, 5-bromo, 5-carboxi o 5-metoxi y A es un grupo 4-piridilo,R, R son hidrogeno, R1 y R1 son metilo y A es 2-furanilo, 2-tienilo o 2-hidroxifenilo. Composiciones farmacéuticas que contienen una dosificacion efectivade por lo menos un compuesto derivado de bis-indol mezclado y adicionado a excipientes o diluyentes farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97110336A EP0887348A1 (en) | 1997-06-25 | 1997-06-25 | Bis-Indole derivatives having antimetastatic activity, a process for their preparation and pharmaceutical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR016283A1 true AR016283A1 (es) | 2001-07-04 |
Family
ID=8226954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980103029A AR016283A1 (es) | 1997-06-25 | 1998-06-24 | Uso de compuestos derivados de bis-indol, compuestos de bis-indol y composiciones farmaceuticas que contienen una dosificacion efectiva de por lo menosun compuesto derivado de bis-indol |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP0887348A1 (es) |
| JP (1) | JP2002507206A (es) |
| KR (1) | KR20010014215A (es) |
| CN (1) | CN1268134A (es) |
| AR (1) | AR016283A1 (es) |
| AU (1) | AU8629598A (es) |
| BR (1) | BR9810947A (es) |
| CA (1) | CA2294250A1 (es) |
| CO (1) | CO4940464A1 (es) |
| HR (1) | HRP980357A2 (es) |
| MA (1) | MA26513A1 (es) |
| TR (1) | TR199903218T2 (es) |
| WO (1) | WO1999000381A1 (es) |
| ZA (1) | ZA985482B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2335254A1 (en) | 1998-07-08 | 2000-01-20 | Harbor Branch Oceanographic Institution, Inc. | Bis-indole derivatives and their use as antiinflammatory agents |
| US7709520B2 (en) | 2000-10-06 | 2010-05-04 | The Texas A&M University System | Diindolylmethane and C-substituted diindolylmethane compositions and methods for the treatment of multiple cancers |
| IT1317925B1 (it) * | 2000-11-03 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Bis-eterocicli ad attivita' antitumorale e chemosensibilizzante. |
| AU2002218075A1 (en) * | 2000-11-08 | 2002-05-21 | K.U. Leuven Research And Development | Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them |
| GB2368843A (en) * | 2000-11-08 | 2002-05-15 | Leuven K U Res & Dev | Non-porphyrin multipurpose contrast agents |
| EP1438044A1 (en) * | 2001-10-19 | 2004-07-21 | Transtech Pharma, Inc. | Bis-heteroaryl alkanes as therapeutic agents |
| US7652036B2 (en) | 2003-02-25 | 2010-01-26 | Topotarget Uk Limited | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors |
| AU2005250116B2 (en) | 2004-06-01 | 2011-01-20 | F. Hoffmann-La Roche Ag | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor |
| US20060084694A1 (en) * | 2004-08-23 | 2006-04-20 | Safe Stephen H | Ligand-dependant activation of Nur77 and uses thereof |
| CN1332948C (zh) * | 2005-05-12 | 2007-08-22 | 苏州大学 | 双吲哚烷基衍生物的合成方法 |
| CN100412058C (zh) * | 2005-05-12 | 2008-08-20 | 苏州大学 | 一种双吲哚烷基化合物的合成方法 |
| TW200716545A (en) | 2005-06-10 | 2007-05-01 | Sigma Tau Ind Farmaceuti | Indole derivatives having anti-tumor activity |
| CN101316818B (zh) | 2005-11-30 | 2011-08-31 | 弗·哈夫曼-拉罗切有限公司 | 3-氨基-1-芳基丙基吲哚类和氮杂取代的吲哚类 |
| CA2632284A1 (en) | 2005-11-30 | 2007-06-07 | F. Hoffmann-La Roche Ag | 3-amino-2-arylpropyl azaindoles and uses thereof |
| ATE517086T1 (de) | 2005-11-30 | 2011-08-15 | Hoffmann La Roche | Verfahren zur synthese von 3-amino-1- arylpropylindolen |
| ES2650810T3 (es) | 2009-01-28 | 2018-01-22 | Karus Therapeutics Limited | Isósteros de Scriptaid y su uso en terapia |
| CN101585800B (zh) * | 2009-06-19 | 2011-06-15 | 中国科学院上海有机化学研究所 | 具有生物活性双吲哚甲烷类化合物 |
| ES2734878T3 (es) | 2011-02-01 | 2019-12-12 | Univ Illinois | Derivados de N-hidroxibenzamida como inhibidores de HDAC y métodos terapéuticos que utilizan los mismos |
| MX364295B (es) | 2012-11-07 | 2019-04-22 | Karus Therapeutics Ltd | Inhibidores de histona desacetilasa novedosos y su uso en terapia. |
| CN105358550B (zh) | 2013-05-10 | 2018-04-06 | 卡鲁斯治疗有限公司 | 组蛋白脱乙酰基酶抑制剂 |
| CN103274987A (zh) * | 2013-06-07 | 2013-09-04 | 华东师范大学 | 3,3-二取代氧化吲哚衍生物及其合成方法和应用 |
| CN104030964B (zh) * | 2014-06-05 | 2016-06-29 | 天津科技大学 | 双吲哚类化合物及合成方法 |
| GB201419228D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| CN107698658B (zh) * | 2015-06-23 | 2021-02-12 | 首都医科大学 | 双[3-(乙酰-Lys-AA-OBzl)-吲哚-2-基]乙烷,其制备,活性和应用 |
| WO2019032902A1 (en) * | 2017-08-10 | 2019-02-14 | The Texas A & M University System | NR4A1 LIGANDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF |
| US20210401803A1 (en) * | 2018-11-21 | 2021-12-30 | The University Of The West Indies | Compounds and uses thereof |
| CN115484822A (zh) * | 2020-02-25 | 2022-12-16 | 得克萨斯农业及机械体系综合大学 | 用于治疗子宫内膜异位症的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4866084A (en) * | 1987-07-17 | 1989-09-12 | Harbor Branch Oceanographic Institution, Inc. | Topsentin compounds effective against viruses and certain tumors |
| US5380746A (en) * | 1989-05-05 | 1995-01-10 | Goedecke Aktiengesellschaft | Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them |
| GB9516943D0 (en) * | 1995-08-18 | 1995-10-18 | Cancer Soc Auckland Div Nz Inc | Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs |
-
1997
- 1997-06-25 EP EP97110336A patent/EP0887348A1/en not_active Withdrawn
-
1998
- 1998-06-19 MA MA25125A patent/MA26513A1/fr unknown
- 1998-06-23 KR KR1019997012300A patent/KR20010014215A/ko not_active Application Discontinuation
- 1998-06-23 EP EP98937539A patent/EP0991645A1/en not_active Withdrawn
- 1998-06-23 TR TR1999/03218T patent/TR199903218T2/xx unknown
- 1998-06-23 WO PCT/EP1998/003837 patent/WO1999000381A1/en not_active Application Discontinuation
- 1998-06-23 CN CN98808565A patent/CN1268134A/zh active Pending
- 1998-06-23 JP JP50527199A patent/JP2002507206A/ja active Pending
- 1998-06-23 AU AU86295/98A patent/AU8629598A/en not_active Abandoned
- 1998-06-23 CA CA002294250A patent/CA2294250A1/en not_active Abandoned
- 1998-06-23 BR BR9810947-2A patent/BR9810947A/pt not_active Application Discontinuation
- 1998-06-24 HR HR97110336.1A patent/HRP980357A2/hr not_active Application Discontinuation
- 1998-06-24 AR ARP980103029A patent/AR016283A1/es unknown
- 1998-06-24 ZA ZA9805482A patent/ZA985482B/xx unknown
- 1998-06-25 CO CO98036361A patent/CO4940464A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP980357A2 (en) | 1999-02-28 |
| CA2294250A1 (en) | 1999-01-07 |
| WO1999000381A1 (en) | 1999-01-07 |
| EP0991645A1 (en) | 2000-04-12 |
| EP0887348A1 (en) | 1998-12-30 |
| CN1268134A (zh) | 2000-09-27 |
| BR9810947A (pt) | 2000-09-26 |
| KR20010014215A (ko) | 2001-02-26 |
| JP2002507206A (ja) | 2002-03-05 |
| MA26513A1 (fr) | 2004-12-20 |
| ZA985482B (en) | 1999-12-24 |
| TR199903218T2 (xx) | 2000-07-21 |
| CO4940464A1 (es) | 2000-07-24 |
| AU8629598A (en) | 1999-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR016283A1 (es) | Uso de compuestos derivados de bis-indol, compuestos de bis-indol y composiciones farmaceuticas que contienen una dosificacion efectiva de por lo menosun compuesto derivado de bis-indol | |
| AR036079A1 (es) | Compuestos de [n-benzoil]-fenilsulfonamida y de n-[fenilsulfonil]-benzamidina;metodos para tratar neoplasias en mamiferos susceptibles, utilizando dichos compuestos y composiciones formuladas con dichos compuestos aplicables en los metodos mencionados | |
| EA200100970A1 (ru) | Аминопроизводные как ингибиторы протеазы | |
| EA200100971A1 (ru) | Новые соединения и композиции в качестве ингибиторов протеазы | |
| DK1615613T3 (da) | Quinoxalinyl-makrocykliske hepatitis C serin protease-inhibitorer | |
| AR014110A1 (es) | Compuestos de 2-aminopiridinas, composiciones farmaceuticas, procedimiento de tratamiento, prevencion e inhibicion | |
| EA200500406A1 (ru) | Активный ингибитор серинпротеазы hcv | |
| AR032605A1 (es) | Derivados (tiona) aminoquinazolinona sustituidos o sales de los mismos, compuestos intermedios de los mismos, y controladores de plagas y un metodo para utilizacion de los mismos | |
| EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
| HUP0203872A2 (hu) | Helyettesített 4-(fenil-N-alkil)-piperazin és piperidinszármazékok, alkalmazásuk dopamin neurotranszmissziós modulátorként és ezeket tartalmazó gyógyszerkészítmények | |
| EA200500814A1 (ru) | Производные пирролопиримидина | |
| AR035863A1 (es) | Ligandos receptores de melanocortina | |
| CO5660262A2 (es) | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa | |
| ES2092580T3 (es) | Derivado de 2-ariltiazol y composicion farmaceutica que contiene el mismo. | |
| ES2130985B1 (es) | Hidroxifeniltriazinas. | |
| ES2187983T3 (es) | Derivados 1,2,3,4-tetrahidronaftaleno sustituidos. | |
| AR020250A1 (es) | Compueto de isoxazolinona, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
| PE20040698A1 (es) | Derivados de isoindolina | |
| DE69434373D1 (de) | Beta-laktame zur Herstellung von Taxanen mit Furyl oder Thienyl substituierter Seitenkette | |
| ES2160163T3 (es) | Composiciones farmaceuticas a base de derivados de la clase de los taxanos. | |
| EE9800144A (et) | Indool-2,3-dioon-3-oksiimi derivaadid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon | |
| ES2156157T3 (es) | Derivado de ciclopenteno heteroaromatico fusionado con una actividad antagonista de la endotelina. | |
| EE02950B1 (et) | Metüleenbisfosfoonhappe esteramiidderivaadid, meetod nende valmistamiseks ja farmatseutiline kompositsioon | |
| AR052223A1 (es) | Metodods y composiciones que utilizan moduladores de pde4 para eltratamiento y el manejo de lesiones del sistema nervioso central | |
| AR040472A1 (es) | Derivado de 2-(fenil)-2h-pirazol-3-carboxilico-n-4(tioxo-heterociclil)fenil-amida e imino-heterociclil derivados y compuestos relacionados, procedimiento, medicamentos, kit |